SUBSCRIBE: Print / eNewsletter
Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.
TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.
The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
One-third of patients with locally advanced non-small cell lung cancer treated with durvalumab developed symptomatic pneumonitis.
The agent has a high affinity and specificity for interleukin-1 beta.
Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.
Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in those with Del19-positive disease.
NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.
The neoantigens found in the patients’ tumors (non-small-cell lung cancer) which were highly dissimilar were enriched for hydrophobic sequences, and correlated with survival rates after the PD-1 checkpoint therapy.
Over that time, the number of active drugs in development has grown by more than 90%.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
